X4 136
Alternative Names: X 4136; X4-136 - X4 PharmaceuticalsLatest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator X4 Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cervical cancer; Malignant melanoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Cervical-cancer in USA (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in USA (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Malignant-melanoma in USA (PO)